Elizabeth Holmes Documentary Opens to $15 Million as Scrutiny Intensifies

A24's You Can See Everything follows Theranos founder Elizabeth Holmes in the 34 days before her prison sentence began, according to Inc.com. Directed by Nathan Fielder and Lance Oppenheim, it revisits a familiar story through unusually close access to its central figure.

The release arrived with little advance public awareness. Deadline reported that fewer than two months before its opening, the public did not even know the documentary existed. Its secrecy became part of the attention surrounding its arrival.

On October 16, IndieWire reported $1.75 million in Thursday previews and an expected opening weekend of $7 million to $8 million. The final weekend estimate would substantially exceed that forecast.

Also on October 16, Holmes' partner Billy Evans defended the decision to participate during an appearance on the All-In podcast. According to Variety, he acknowledged that she looked "insane" in the trailer but urged viewers to "make up your own mind."

By October 17, the interest was spreading beyond ordinary ticket sales. Business Insider reported that technology companies and venture capital firms were hosting private screenings. Forbes also reported rising engagement with the Hulu series The Dropout and journalist John Carreyrou's book Bad Blood ahead of the film's release.

On October 18, IndieWire reported a $15 million opening. The Hill reported 2,000 sold-out shows in the limited US release. The next day, the BBC put the opening footprint at 855 screens across the United States and Canada for the roughly three-hour film.

On October 19, attention shifted further toward the relationship between Holmes and the filmmakers. Variety reported Fielder's account that Holmes called him from prison shortly before release and repeatedly told him, "I trust you." Separately, Forbes reported Theranos whistleblower Tyler Shultz's allegation that Holmes "completely misled" Fielder about the company's technology in one scene.

The $15 million opening is the clearest measure of the film's commercial breakthrough. Reports differ on its historical ranking: The Daily Beast called it the biggest documentary opening since 2013, CNN described it as the biggest in more than 20 years, and TechCrunch called it the second-biggest ever. Those descriptions are not consistent across the supplied coverage.

The critical discussion is also broader than whether Holmes comes across sympathetically. Reason framed the film as an act of radical empathy, while Business Insider focused on the unsettling experience of wanting to believe her. Shultz's allegation adds a specific challenge to the account she gives on camera.

The next commercial test is whether the opening-weekend interest holds. Forbes described the film's popularity as snowballing on October 20, but the supplied coverage does not yet establish its longer-term box office performance.

Awards attention is building, too. Deadline discussed Oscar possibilities, including an acting category, while /Film argued for a nomination it considered unlikely. These remain assessments of the film's prospects, not nomination results.